drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody
drug_description
Rocatinlimab (AMG 451/KHK4083) is a subcutaneous monoclonal antibody targeting OX40 (CD134). It inhibits OX40–OX40L costimulatory signaling and depletes OX40-expressing activated effector/memory T cells, reducing type 2/Th2 inflammation in atopic dermatitis.
nci_thesaurus_concept_id
C184936
drug_mesh_term
KHK4083
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Rocatinlimab is a subcutaneous monoclonal antibody that binds OX40 (CD134) on activated effector/memory T cells, blocking OX40–OX40L costimulatory signaling and depleting OX40-expressing T cells, thereby reducing T-cell activation and type 2/Th2-driven inflammation in atopic dermatitis.
drug_name
Rocatinlimab
nct_id_drug_ref
NCT05899816